AU674302B2 - Treatment for inflammatory bowel disease - Google Patents

Treatment for inflammatory bowel disease Download PDF

Info

Publication number
AU674302B2
AU674302B2 AU36059/93A AU3605993A AU674302B2 AU 674302 B2 AU674302 B2 AU 674302B2 AU 36059/93 A AU36059/93 A AU 36059/93A AU 3605993 A AU3605993 A AU 3605993A AU 674302 B2 AU674302 B2 AU 674302B2
Authority
AU
Australia
Prior art keywords
antibody
vla
inflammatory bowel
bowel disease
international
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU36059/93A
Other languages
English (en)
Other versions
AU3605993A (en
Inventor
Roy R. Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25268692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU674302(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AU3605993A publication Critical patent/AU3605993A/en
Application granted granted Critical
Publication of AU674302B2 publication Critical patent/AU674302B2/en
Assigned to BIOGEN IDEC MA INC. reassignment BIOGEN IDEC MA INC. Request to Amend Deed and Register Assignors: BIOGEN, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU36059/93A 1992-02-12 1993-02-02 Treatment for inflammatory bowel disease Expired AU674302B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83513992A 1992-02-12 1992-02-12
US835139 1992-02-12
PCT/US1993/000924 WO1993015764A1 (en) 1992-02-12 1993-02-02 Treatment for inflammatory bowel disease

Publications (2)

Publication Number Publication Date
AU3605993A AU3605993A (en) 1993-09-03
AU674302B2 true AU674302B2 (en) 1996-12-19

Family

ID=25268692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36059/93A Expired AU674302B2 (en) 1992-02-12 1993-02-02 Treatment for inflammatory bowel disease

Country Status (11)

Country Link
EP (1) EP0625912B1 (da)
JP (3) JPH07506566A (da)
AT (1) ATE151642T1 (da)
AU (1) AU674302B2 (da)
CA (1) CA2129637C (da)
DE (1) DE69309906T2 (da)
DK (1) DK0625912T3 (da)
ES (1) ES2103468T3 (da)
GR (1) GR3024041T3 (da)
HK (1) HK1007683A1 (da)
WO (1) WO1993015764A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
ES2424292T3 (es) * 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100628818B1 (ko) 1998-09-14 2006-09-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 인테그린 길항제를 사용하여 다발성 골수종 및 골수종에의한 골흡수를 치료하는 방법
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
RU2359697C2 (ru) 2002-02-25 2009-06-27 Элан Фармасьютикалз, Инк. Введение средств для лечения воспаления
CN1917881B (zh) 2003-12-22 2014-11-26 味之素株式会社 新型苯基丙氨酸衍生物
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP4652356B2 (ja) 2007-02-26 2011-03-16 アルプス電気株式会社 ターンシグナルスイッチ装置
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
EP3466977B1 (en) 2010-04-16 2022-01-05 Biogen MA Inc. Anti-vla-4 antibodies
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN107998388B (zh) 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
CN109884295B (zh) * 2017-12-25 2022-03-08 苏州和锐生物科技有限公司 假单胞菌多肽、抗体捕获器件及试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2782992A (en) * 1991-10-01 1993-05-03 General Hospital Corporation, The Preventing allograft rejection with antibodies to adhesion molecules
AU3431793A (en) * 1992-01-13 1993-08-03 Biogen Idec Ma Inc. Treatment for asthma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2064327T3 (es) * 1987-11-02 1995-02-01 Baylor College Medicine Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2782992A (en) * 1991-10-01 1993-05-03 General Hospital Corporation, The Preventing allograft rejection with antibodies to adhesion molecules
AU3431793A (en) * 1992-01-13 1993-08-03 Biogen Idec Ma Inc. Treatment for asthma

Also Published As

Publication number Publication date
ATE151642T1 (de) 1997-05-15
EP0625912B1 (en) 1997-04-16
JPH07506566A (ja) 1995-07-20
HK1007683A1 (en) 1999-04-23
DE69309906D1 (de) 1997-05-22
EP0625912A1 (en) 1994-11-30
JP4108572B2 (ja) 2008-06-25
CA2129637A1 (en) 1993-08-19
DK0625912T3 (da) 1997-10-27
JP2007045843A (ja) 2007-02-22
JP2004002472A (ja) 2004-01-08
CA2129637C (en) 1999-05-04
ES2103468T3 (es) 1997-09-16
AU3605993A (en) 1993-09-03
DE69309906T2 (de) 1997-11-06
GR3024041T3 (en) 1997-10-31
WO1993015764A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
AU674302B2 (en) Treatment for inflammatory bowel disease
Rice et al. Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes. A CD11/CD18-independent adhesion mechanism.
US6482409B1 (en) Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein
van Dinther-Janssen et al. The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium.
Nakada et al. Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitment
AU649682B2 (en) Humanized chimeric anti-ICAM-1 antibodies, methods of preparation and use
CA2140538C (en) Monoclonal antibodies that block ligand binding to the cd22 receptor in mature b cells
US5475091A (en) R6-5-D6, an antibody which binds intercellular adhesion molecule-1
Mittler et al. Generation and characterization of monoclonal antibodies reactive with human B lymphocytes.
US20020197233A1 (en) Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
IE881322L (en) Intercellular adhesion molecules and their binding ligands
SK139593A3 (en) Intercellular adhesion molecules-3-and its binding ligands
Huang et al. A lymphocyte homing receptor (L-selectin) mediates the in vitro attachment of lymphocytes to myelinated tracts of the central nervous system.
Chuluyan et al. Domains 1 and 4 of vascular cell adhesion molecule-1 (CD106) both support very late activation antigen-4 (CD49d/CD29)-dependent monocyte transendothelial migration.
US5891841A (en) Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
Yan et al. Leukocyte recruitment into human skin transplanted onto severe combined immunodeficient mice induced by TNF-alpha is dependent on E-selectin.
US5512442A (en) Detection of vascular adhesion protein-1 (VAP-1)
US20090035321A1 (en) Intercellular adhesion molecules and their binding ligands
AU3431893A (en) Antibodies recognizing the fourth immunoglobulin-like domain of VCAM1
US20130011390A1 (en) Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
EP0726942B1 (en) Monoclonal antibodies to foam cells and their pharmaceutical and diagnostic use
WO1993002698A1 (en) Monoclonal antibodies to leukocyte adhesion molecule-1
Kavanaugh Antiadhesion therapy in rheumatoid arthritis: A review of recent progress